Biological
Laromestrocel clinical trials
Also written OSSM-001 and BM-MSC.
- studies test it
- 13
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How studies write it
Studies that test it under each name
Name
Brand
Development codes
Other names
Studies by the year they started
13 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 2 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 6
Longeveron Inc. (5) · Ossium Health, Inc. (2) · Mayo Clinic (1) · Catherine Bollard (1) · University of Jordan (1) · Michael A. Matthay (1) · Ottawa Hospital Research Institute (1) · Joshua M Hare (1)
Studies
Open first, then newest update. How each study uses laromestrocel is read from its arms, and is right about nine times in ten.
Testing it · 13
- Allogeneic BM-MSCs in Patients With Painful Lumbar Facet ArthropathyActive, not recruitingPhase 2Mayo ClinicNCT06001853Written as BM-MSC injection
- Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP)Active, not recruitingPhase 1Catherine BollardNCT04236479Written as BM-MSC
- AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PErifistula iNjEctions (GALENE)WithdrawnPhase 1Joshua M HareNCT02677350Written as Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)
- The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult HumansActive, not recruitingPhase 1University of JordanNCT04815213Written as expanded autologous bone marrow derived MSC Intravaginally
- Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)Active, not recruitingPhase 1Longeveron Inc.NCT04629105Written as Longeveron Mesenchymal Stem Cells (LMSCs)
- Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)Active, not recruitingPhase 1/2Longeveron Inc.NCT03525418Written as Longeveron Mesenchymal Stem Cells
- Mesenchymal Stem Cells (MSCs) for Perianal FistulaWithdrawnPhase 1Ossium Health, Inc.NCT05407766Written as OSSM-001
- Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD)WithdrawnPhase 1Ossium Health, Inc.NCT05443464Written as OSSM-001
- Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging FrailtyCompletedPhase 1/2Longeveron Inc.NCT02982915Written as Longeveron Mesenchymal Stem Cells (LMSCs)
- Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging FrailtyCompletedPhase 2Longeveron Inc.NCT03169231Written as Longeveron Mesenchymal Stem Cells (LMSCs)
- Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's DiseaseCompletedPhase 1Longeveron Inc.NCT02600130Written as Longeveron Mesenchymal Stem Cells
- Cellular Immunotherapy for Septic ShockStatus unknownPhase 2Ottawa Hospital Research InstituteNCT03369275Written as Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
- Human Mesenchymal Stem Cells For Acute Respiratory Distress SyndromeCompletedPhase 1Michael A. MatthayNCT01775774Written as Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells